Benzenamine, 2-fluoro-5-methoxy-N-methyl- | 502435-25-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: Benzenamine, 2-fluoro-5-methoxy-N-methyl-
• 英文别名: 2-fluoro-5-methoxy-N-methylaniline
• CAS: 502435-25-8
• 化学式: C₈H₁₀FNO
• 分子量: 155.17
• InChiKey: WVJLYSAXAFISSC-UHFFFAOYSA-N

物化性质

• 沸点：
  244.3±30.0 °C(Predicted)
• 密度：
  1.131±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] DIRECTED CONJUGATION TECHNOLOGIES<br/>[FR] TECHNOLOGIES DE CONJUGAISON DIRIGÉE
  申请人：KLEO PHARMACEUTICALS INC

  公开号：WO2021102052A1

  公开（公告）日：2021-05-27

  Among other things, the present disclosure provides technologies for site-directed conjugation of various moieties of interest to target agents. In some embodiments, the present disclosure utilizes target binding moieties to provide high conjugation efficiency and selectivity. In some embodiments, provided technologies are useful for preparing antibody conjugates.

  本公开提供了用于将各种感兴趣的分子与目标剂进行定点偶联的技术。在某些实施方式中，本公开利用目标结合分子以提供高偶联效率和选择性。在某些实施方式中，所提供的技术可用于制备抗体偶联物。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
  申请人：KYOWA HAKKO KIRIN CO., LTD.

  公开号：US20150299214A1

  公开（公告）日：2015-10-22

  The present invention provides a heterocyclic compound represented by the following formula (I), wherein X A represents CH and the like, R 1 represents cycloalkyl optionally having substituent(s) and the like, L represents a bond and the like, Y A represents —NH— and the like, R 2 represents a hydrogen atom and the like, R 3A represents the following formula (R 3A -1) (wherein, R 3 represents hydroxy and the like) and the like, and R 4A represents the following formula (R 4A -1) (wherein, R 4 and R 5 are the same or different and each represents a hydrogen atom and the like) and the like, or a pharmaceutically acceptable salt thereof, which is useful as a prophylactic and/or therapeutic agent for skin diseases and the like, and the like.

  本发明提供一种杂环化合物，其化学式表示为（I），其中XA代表CH等，R1代表环烷基，可选地具有取代基等，L代表键等，YA代表—NH—等，R2代表氢原子等，R3A代表下式（R3A-1）（其中，R3代表羟基等）等，R4A代表下式（R4A-1）（其中，R4和R5相同或不同，且每个代表氢原子等）等，或其药学上可接受的盐，其作为预防和/或治疗皮肤疾病等的药物具有用途。
• [EN] ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT UTILISANT UNE TECHNOLOGIE DE COUPLAGE POUR ADMINISTRER DES AGENTS CYTOTOXIQUES
  申请人：BIOHAVEN THERAPEUTICS LTD

  公开号：WO2022246086A1

  公开（公告）日：2022-11-24

  Among other things, the present disclosure provides technologies for site-directed conjugation of various moieties of interest to target agents. In some embodiments, the present disclosure utilizes target binding moieties to provide high conjugation efficiency and selectivity. In some embodiments, provided technologies are useful for preparing antibody conjugates.

  除其他事项外，本公开提供了用于将各种感兴趣的物质定向结合到目标试剂上的技术。在某些实施例中，本公开利用目标结合物质提供高结合效率和选择性。在某些实施例中，提供的技术对于制备抗体结合物很有用。
• Hepatitis B antiviral agents
  申请人：Novira Therapeutics, Inc.

  公开号：US10196376B2

  公开（公告）日：2019-02-05

  The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

  本发明包括一种在有需要的个体中抑制、抑制或预防 HBV 感染的方法，包括向该个体施用治疗有效量的至少一种本发明化合物。
• SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS
  申请人：Janssen Pharmaceuticals Inc.

  公开号：EP2454239B1

  公开（公告）日：2014-08-13